Breast Care最新文献

{"title":"Magnetic Marker Artefacts on Magnetic Resonance Imaging and Localization Precision: Considerations for Targeted Axillary Dissection after Neoadjuvant Therapy.","authors":"Muharrem Oner, Kefah Mokbel","doi":"10.1159/000546482","DOIUrl":"10.1159/000546482","url":null,"abstract":"","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 5","pages":"375-377"},"PeriodicalIF":2.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145343599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain Metastases of a Triple-Negative Breast Cancer: A Systematic Literature Review of the Systemic Treatment Options.","authors":"Patricia von Kroge, Kerstin Riecke, Johann Kornowski, Barbara Schmalfeldt, Volkmar Müller, Elena Laakmann","doi":"10.1159/000545549","DOIUrl":"10.1159/000545549","url":null,"abstract":"<p><strong>Background: </strong>The development of brain metastases (BM) is an increasing concern for patients with metastatic triple-negative breast cancer (mTNBC). This systematic review aimed to summarize the current evidence regarding systemic treatment options for patients with mTNBC and BM.</p><p><strong>Methods: </strong>A systematic literature review was conducted by searching the database PubMed with the keywords metastatic triple-negative breast cancer,\" \"therapy\" and \"brain metastases.\" Articles were screened and included if they focused on the treatment of mTNBC. Both prospective and retrospective clinical trials were eligible for inclusion.</p><p><strong>Results: </strong>The literature search identified 3,413 articles, of which eight met the inclusion criteria. These studies provided evidence for the treatment of patients with stable BM using sacituzumab govitecan, pembrolizumab combined with chemotherapy, trastuzumab deruxtecan (T-DXd), nab-paclitaxel combined with cisplatin, and talazoparib. No evidence was found for active BM or leptomeningeal metastases.</p><p><strong>Conclusion: </strong>Based on the current evidence discussed in this review, testing for programmed death-ligand 1 (PD-L1), HER2, including immunohistochemistry (IHC) status as well as germline BRCA 1/2 mutation, should be considered in all mTNBC patients with BM as the results have significant treatment implications. Moreover, PD-L1 expression should be evaluated on primary tumor and (if tissue sample available) reevaluated on BMs if negative on primary BC, to maximize the opportunity for treatment with immune checkpoint inhibitors. Furthermore, if brain tissue is available, HER2 IHC should also be tested in order to evaluate the status switch and to assess the therapeutic effectiveness of treatment with T-DXd. Further targeted agents are urgently needed in order to improve the survival of patients with TNBC and BM.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"364-374"},"PeriodicalIF":2.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Online Training to Increase Genetic and Risk Literacy in Physicians Counseling Breast and Ovarian Cancer Patients for Genetic Testing.","authors":"Kerstin Rhiem, Clara Breidenbach, Anke Waha, Britta Blümcke, Christine Fischer, Tiemo Grimm, Andrea Hahne, Eric Hahnen, Anke Harney, Jan Hauke, Karin Kast, Friedhelm Meier, Anne Quante, Alexander Volk, Tanja Zimmermann, Simone Wesselmann, Rita Schmutzler","doi":"10.1159/000545408","DOIUrl":"10.1159/000545408","url":null,"abstract":"<p><strong>Introduction: </strong>The increasing use of germline genetic testing for the clinical management of patients with a family history of breast and ovarian cancer requires an improvement in the genetic and risk literacy of physicians and healthcare professionals. In order to offer high-quality care throughout Germany, from genetic counseling to risk-adapted prevention, the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) and the German Cancer Society (DKG) have established a nation-wide cooperation partner network with certified gynecological and breast cancer centers. As a core element of this cooperation, an online-based training program has been developed in which the \"state-of-the-art knowledge\" on the topic is conveyed.</p><p><strong>Methods: </strong>The training is aimed at physicians and healthcare professionals working in the specialized centers of the GC-HBOC/certified centers for familial breast and ovarian cancer (FBREK centers) or the cooperating certified gynecological and breast cancer centers. It consists of an online-based part (15 lectures) covering interdisciplinary basics and competencies on political frameworks, genetic and nongenetic risk factors including individual risk calculation, and nondirective communication on risk-adapted prevention options. Patient involvement with voting rights during the development and implementation of the training increased its accuracy of fit for patient needs. After a successful online knowledge test, employees of certified gynecological and breast cancer centers participate in a 1-day, on-site internship at an FBREK center with which a cooperation is planned.</p><p><strong>Results: </strong>From November 2021 to July 2024, 1,860 participants registered for the online training, of which 1,329 have started to work on the content. So far, 898 participants have passed the online knowledge test. More than 560 participants took part in the accompanying evaluation in which the majority stated that the course helped to increase their professional knowledge, it was relevant to their practical medical work, and it contributed to a more confident approach to patients with a family history of cancer. Most participants stated that it was worthwhile participating in the training in terms of time and organization and that the content, didactics, visual presentations, and comprehensibility were appropriate.</p><p><strong>Conclusion: </strong>The online-based training serves to impart and expand interdisciplinary knowledge and skills in genetics and risk counseling. It is well received, has been positively evaluated and the format proves to be suitable for strengthening the networked care of patients across sectoral boundaries and promoting the rapid translation of new research findings into clinical practice within the framework of knowledge-generating care.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"305-313"},"PeriodicalIF":2.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Safety of Elacestrant in Patients with Breast Cancer: Insights from Food and Drug Administration Adverse Event Reporting System Database Analysis.","authors":"Tailong Lv, Wenkai Bao, Shouqiang Chen","doi":"10.1159/000546678","DOIUrl":"10.1159/000546678","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to evaluate the safety profile of elacestrant in real-world settings using data from the FDA adverse event (AE) reporting system (FAERS) database, offering insights to inform clinical use.</p><p><strong>Methods: </strong>Data are collected from the FAERS database spanning the first quarter of 2023 through the third quarter of 2024. AEs associated with elacestrant are identified using reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multinomial gamma Poisson shrinkageanalyses. The temporal distribution of AEs is assessed using Weibull distribution to evaluate the drug's safety comprehensively.</p><p><strong>Results: </strong>Reports of 6,476 AEs with elacestrant as the primary suspect drug are identified, spanning 27 organ systems. A total of 53 preferred terms signal are detected across four algorithms, including known adverse reactions such as nausea, vomiting, fatigue, elevated blood cholesterol, and musculoskeletal pain. Potential new AEs, including pathological fractures, gastroesophageal reflux disease, hypokalemia, lymphedema, and dehydration, are also identified. The median onset time for elacestrant-related AEs is 44 days, with most events occurring within the first month of treatment.</p><p><strong>Conclusion: </strong>This study offers real-world insights into elacestrant usage, confirming known adverse reactions and identifying previously unreported events. These findings provide valuable guidance for clinicians in minimizing drug risks during treatment.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"348-363"},"PeriodicalIF":2.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistence to Adjuvant Endocrine Therapy for Breast Cancer in Botswana: An Observational Cohort Analysis.","authors":"Arthur T Johnson, Peter Vuylsteke, Taolo Ntloedibe, Jose Euberto Mendez Reyes, Oaitse John, James R Wester, Elizabeth Y Chiao, Scott L Dryden-Peterson","doi":"10.1159/000547028","DOIUrl":"10.1159/000547028","url":null,"abstract":"<p><strong>Purpose: </strong>Daily use of adjuvant endocrine therapy significantly reduces the risk of recurrence and death of estrogen-positive breast cancer; however, it remains unclear to what degree patients persist with endocrine therapy in southern Africa.</p><p><strong>Methods: </strong>Female patients, >18 years of age, with estrogen receptor-positive breast cancer within the Thabaste Cancer Cohort in Botswana were identified and contacted to determine if they remained persistent to their adjuvant endocrine therapy. Non-persistence was defined as self-reported discontinuation of endocrine therapy for longer than 180 days. Clinical and demographic data were compared between persistent and nonpersistent patients.</p><p><strong>Results: </strong>Overall, 133 patients with estrogen receptor-positive breast cancer were identified of which 91 were prescribed adjuvant endocrine therapy. Tamoxifen was prescribed for 56 (63%) and anastrozole for 33 (37%) women. Adjuvant endocrine therapy was interrupted in 45 (50%) patients; however, only 8 (8.8%) were nonpersistent. Sociodemographic and clinical characteristics were similar between persistent and nonpersistent patients, except significantly higher income was noted in those persistent to endocrine therapy. Medication non-availability was the most common reason noted for interruption of endocrine therapy.</p><p><strong>Conclusion: </strong>Interruptions to adjuvant endocrine therapy in Botswana is common, but rates of persistence remain high. Medication stockout was the most common reasons for interruption of adjuvant endocrine therapy.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological Factors Affecting Positive Margins after Breast-Conserving Surgery: A Comparative Study of Low- and High-Volume Hospitals.","authors":"Seher Makineli, Sofie A M Gernaat, Milan C Richir, Wouter B Veldhuis, Liesbeth M Veenendaal, Maaike R Moman, Patrick I Ferdinandus, Menno R Vriens, Paul J van Diest, Wies Maarse, Arjen J Witkamp","doi":"10.1159/000544904","DOIUrl":"10.1159/000544904","url":null,"abstract":"<p><strong>Purpose: </strong>Positive margins after breast-conserving surgery (BCS) are an important risk factor for local tumor recurrence and the need for re-excision in women with breast cancer. It remains unclear which factors collectively influence positive margins after BCS and whether the outcomes vary among hospitals. This study investigated the occurrence and risk factors of positive margins after BCS in women with breast cancer in two Dutch hospitals.</p><p><strong>Methods: </strong>Data were collected retrospectively from medical records of women who were diagnosed with newly invasive breast carcinoma or carcinoma in situ and underwent primary BCS between January 1, 2018 and December 31, 2020 in two Dutch hospitals.</p><p><strong>Results: </strong>A total of 423 cases (410 patients) were included, with a median age of 58 years (interquartile range 51-66). On average, the positive margin rate after BCS was 8.0%, which was significantly higher in the low-volume hospital (14.9%) than in the high-volume hospital (5.9%). Invasive lobular carcinoma (odds ratio [OR] = 4.97, confidence interval [CI] = 1.91-12.94), postoperative tumor size (OR = 1.07, CI = 1.03-1.11), low hospital volume (OR = 3.90, CI = 1.58-9.66), and lumpectomy size (OR = 0.97, CI = 0.94-1.00) were significantly associated with positive margins after BCS.</p><p><strong>Conclusion: </strong>Positive margin rate after BCS was low, with 8.0% among all cases and varied significantly between the hospitals. Patient-, tumor-, radiological-, and surgery-related factors may contribute to these variations. An optimized collaborative multidisciplinary approach to breast cancer care, particularly between radiologists and surgeons, should be strived to achieve improved oncological outcomes in women after BCS.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 4","pages":"238-247"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144943808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Idiopathic Granulomatous Mastitis: A Consensus Report on Treatment and Follow-Up Approaches Based on the Turkish Clinical Classification.","authors":"Mustafa Emiroglu, Kenan Cetin, Kerim Bora Yilmaz, Mehmet Velidedeoglu, Sadullah Girgin, Alper Akcan, Ozgur Aytac, Murat Akın, Hande Koksal, Neslihan Cabioglu, Nuh Zafer Canturk, Bahadır Gulluoglu","doi":"10.1159/000544967","DOIUrl":"10.1159/000544967","url":null,"abstract":"<p><strong>Objective: </strong>The second consensus study on idiopathic granulomatous mastitis (IGM) aimed to establish treatment options based on the clinical classification proposed in the first consensus, standardize criteria for treatment discontinuation, and develop follow-up protocols.</p><p><strong>Method: </strong>A structured methodology, identical to the first consensus study, was employed. An 11-member working group of breast surgeons experienced in IGM from various clinics across the country was formed. The modified Delphi method was used, with a consensus threshold of 80% agreement.</p><p><strong>Results: </strong>Three voting rounds were conducted to develop the IGM treatment algorithm. In Round 1, observation was established as the first-line option for Type 1 disease (81%) and pregnancy/lactation cases (85%). Round 2 achieved consensus on systemic steroids (SS) as the first-line treatment for Type 3 cases (84%), combination therapies for resistant cases (82%), and reclassification of recurrent cases to guide treatment planning (94%). In Round 3, consensus was reached on the use of immunosuppressive therapy (IMT) for cases where steroids are contraindicated in Type 3 (81%), the use of IMT for resistant cases (93%), avoiding surgery as the first-line option for Type 1 cases (81%), and requiring complete clinical and radiological response before discontinuing treatment (81%). However, no consensus was reached on the first-line treatment for Type 2 disease.</p><p><strong>Conclusion: </strong>This consensus study successfully developed a treatment algorithm for IGM, prioritizing observation for Type 1 disease and cases involving pregnancy or lactation, and recommending systemic steroids (SS) and immunosuppressive therapies for Type 3 cases. The findings underscore the critical importance of achieving complete clinical and radiological remission before discontinuing treatment. However, the lack of consensus on the treatment of Type 2 disease highlights the need for further research into this challenging subtype.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 4","pages":"248-255"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144943797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Granulomatous Mastitis Is Not as Benign as You Might Think: What Doctors Need to Know about the Lived Experience of People with This Rare Disease.","authors":"Mary McNaughton-Cassill, Joseph Torres, Sandra Pahl, Carolyn Cassill","doi":"10.1159/000544888","DOIUrl":"10.1159/000544888","url":null,"abstract":"<p><strong>Introduction: </strong>Granulomatous mastitis (GM) is a rare, benign disease characterized by painful inflammation, and abscesses typically on only one breast. Treatments include antibiotics, steroid treatments, and surgery, but there is no cure. The current study was designed to assess patient perceptions of living with the disease and what they would like physicians to know about their needs.</p><p><strong>Methods: </strong>The advent of the internet has enabled patients with rare conditions to reach out to support each other. Participants on a GM patient only Facebook site were asked if they would be willing to complete an anonymous survey regarding their experiences living with the disease. They completed a demographic survey, as well as measures of their pain and discomfort, psychological state, and social support.</p><p><strong>Results: </strong>The results indicated that patients with GM believe they need more help managing their pain discomfort and fatigue. They also report significant levels of depression and anxiety suggesting that they could also benefit from more psychological support.</p><p><strong>Discussion: </strong>Living with this painful, disfiguring disease for which there is no cure has a negative impact on people's mental and physical well-being. Practitioners who treat people with GM should consider providing their patients with specific pain management options, strategies for coping with fatigue and referrals to mental health practitioners who specialize in coping with chronic disease. Such efforts would help improve patient's quality of life and ability to cope with this \"benign\" but life altering disease.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 4","pages":"221-227"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144943845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"St. Gallen/Vienna 2025 Summary of Key Messages on Therapy in Early Breast Cancer from the 2025 St. Gallen International Breast Cancer Conference.","authors":"Nina Ditsch, Michael Gnant, Christoph Thomssen, Nadia Harbeck","doi":"10.1159/000546080","DOIUrl":"10.1159/000546080","url":null,"abstract":"<p><strong>Background: </strong>In 2025, the St. Gallen Conference was held from March 12th-15th, with the largest attendance since the pandemic and more than 3,000 participants from over 100 countries.</p><p><strong>Summary: </strong>The conference chairs professionally guided through the program on Early Breast Cancer, featuring abstracts submitted from all over the world. In addition, Prof. Dr. Herold J. Burstein (USA) led the panel through the difficult topics of local and systemic treatment modalities in an excellent, clearly structured and engaging way. Almost 80 experts from all continents and more than 30 nations formed the panel and summarized the current literature in excellent presentations and discussions.</p><p><strong>Key messages: </strong>Final voting covered the topics of genetic testing, DCIS, breast and axillary surgery, radiation therapy, systemic treatment based on subtypes, treatment of the elderly, therapy of local-regional recurrence and oligometastatic breast cancer.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"288-297"},"PeriodicalIF":2.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Patient Satisfaction and Quality of Life Using the BREAST-Q Questionnaire in Oncoplastic Breast-Conserving Surgery Techniques for Centrally Located Breast Cancer.","authors":"Halit Özgül, Gülşah Çelik, Remzi Can Çakir, Ömer Çelik, Ali Çelik","doi":"10.1159/000544114","DOIUrl":"10.1159/000544114","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to retrospectively compare the impact of level-2 oncoplastic techniques - doughnut, lateral, vertical, and racket mastopexy - on patient satisfaction and quality of life in centrally located breast cancer surgery, using the BREAST-Q questionnaire.</p><p><strong>Methods: </strong>This study included patients aged 18-65 who underwent oncoplastic surgery for centrally located breast tumors at a teaching hospital between January 2021 and August 2024. The BREAST-Q questionnaire, which assesses satisfaction with the breast, psychosocial well-being, and sexual health, was administered at least 3 months post-surgery and radiotherapy. Demographic and clinical data were collected from the patient records.</p><p><strong>Results: </strong>Among the 142 patients included in the study, 90 underwent doughnut mastopexy, while 52 received other techniques. The BREAST-Q scores indicated higher satisfaction with breasts (92.28%), psychosocial well-being (87.41%), and sexual well-being (86.39%) in the doughnut mastopexy group compared to the other techniques (<i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Doughnut mastopexy yielded better outcomes than other techniques, likely because of minimal scarring, reduced need for contralateral procedures, and improved aesthetic results. These findings suggest that this technique offers superior patient satisfaction for centrally located breast tumors.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 3","pages":"145-153"},"PeriodicalIF":2.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}